Opus Genetics shares fall 4.17% intraday after FDA clearance of IND for OPGx-BEST1 gene therapy.

Opus Genetics, Inc. declined 4.17% in intraday trading, following the announcement that the FDA has accepted its Investigational New Drug (IND) application for OPGx-BEST1, a gene therapy for the treatment of bestrophin-1 (BEST1)-related inherited retinal disease. The company also revealed that a Phase 1/2 trial is expected to initiate in the second half of 2025.